# vTv Therapeutics Inc.: overview VTVT · Nasdaq · CIK 1641489 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vtvt.md) · [Financials](/companies/vtvt/financials.md) · [Filings](/companies/vtvt/filings.md) · [Insiders](/companies/vtvt/insiders.md) Latest reported revenue: [$0](/filings/0001641489-26-000030.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001641489-26-000030). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [0.0](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [36.8](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(28776.5%) d](/filings/0001641489-26-000010.md) | not reported | not reported | not reported | not reported | [63.1%](/filings/0001641489-26-000020.md) | not reported | | Net margin | % | not reported | [(21376.5%) d](/filings/0001641489-26-000010.md) | not reported | not reported | not reported | not reported | [65.5%](/filings/0001641489-26-000020.md) | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.0](/filings/0001641489-24-000012.md) | [2.0](/filings/0001641489-25-000014.md) | [0.0](/filings/0001641489-26-000010.md) | [1.0](/filings/0001641489-26-000010.md) | [0.0](/filings/0001641489-26-000010.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(540.9%)](/filings/0001641489-24-000012.md) | [(1116.9%)](/filings/0001641489-25-000014.md) | not reported | [(2377.6%)](/filings/0001641489-26-000010.md) | not reported | | Net margin | % | [(324.3%)](/filings/0001641489-24-000012.md) | [(949.7%)](/filings/0001641489-25-000014.md) | not reported | [(1815.3%)](/filings/0001641489-26-000010.md) | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(19.3)](/filings/0001641489-24-000012.md) | [(16.0)](/filings/0001641489-25-000014.md) | [(19.1)](/filings/0001641489-26-000010.md) | [(25.3)](/filings/0001641489-26-000010.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vtvt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $11.2m | 298,496 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $10.2m | 269,874 | | Added +63,586 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $9.8m | 260,391 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $6.1m | 163,000 | | Unchanged | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $5.6m | 148,314 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.6m | 94,463 | | Reduced −14,459 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $3.2m | 85,192 | | Reduced −54,386 | | [Aisling Capital Management LP](/funds/1766721.md) | 2026-06-30 | $1.9m | 50,000 | | New +50,000 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.5m | 39,560 | | Added +26,171 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.2m | 32,470 | | Reduced −416 | ## Recent filings [All 594 filings](/companies/vtvt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:31 ET | [8-K](/filings/0001641489-26-000032.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001641489-26-000032 | | 2026-08-06 | 20:24 ET | [10-Q](/filings/0001641489-26-000030.md) | Quarterly report, period 2026-06-30 | 0001641489-26-000030 | | 2026-08-06 | 20:18 ET | [8-K](/filings/0001641489-26-000029.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001641489-26-000029 | | 2026-06-29 | 20:14 ET | [8-K](/filings/0001641489-26-000024.md) | 5.07 Shareholder vote results | 0001641489-26-000024 | | 2026-05-13 | 21:20 ET | [8-K](/filings/0001193125-26-221971.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-221971 | | 2026-05-13 | 20:21 ET | [10-Q](/filings/0001641489-26-000020.md) | Quarterly report, period 2026-03-31 | 0001641489-26-000020 | | 2026-05-13 | 20:18 ET | [8-K](/filings/0001641489-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001641489-26-000019 | | 2026-04-28 | 20:21 ET | [DEF 14A](/filings/0001641489-26-000015.md) | Proxy statement, period 2026-06-10 | 0001641489-26-000015 | | 2026-03-10 | 20:37 ET | [8-K](/filings/0001641489-26-000012.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641489-26-000012 | | 2026-03-10 | 20:35 ET | [8-K](/filings/0001641489-26-000011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001641489-26-000011 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001641489-26-000010.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3caab304-f6be-4688-a83a-bb7048e61210) ## About the filer - CIK: 1641489 - Tickers: VTVT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.